TAGCyx has signed a collaborative research agreement with GlyTech, Inc. (CEO: Hiroaki Asai, Head office: Kyoto) in relation to glycosylation techniques for aptamer therapeutics.
TAGCyx possesses a leading, proprietary, artificial nucleic acid base pair technology, used to produce high affinity and selective “Xenoligo®” DNA aptamers, while GlyTech possesses a unique platform for the production of an extensive variety of highly purified human N-glycans, and the technology to attach them to a specific site on target molecules such as synthetic peptides.
Modifying Xenoligo® with GlyTech’s glycosylation technology is expected to increase the functionality of aptamers and add high value to them.
Dr Chizuko Koseki, Chief Executive Officer of TAGCyx added “We are pleased to enter into a collaboration with GlyTech, bringing together two leading technologies to potentially enhance therapeutics research”.
TAGCyx has signed collaborative research agreement with Chiome Bioscience Inc. (CEO: Shigeru Kobayashi, Head office: Tokyo, listed on Tokyo Stock Exchange Mothers Index: 4583) in relation to innovative aptamer therapeutics.
TAGCyx possesses a leading, proprietary, artificial nucleic acid base pair technology (Xenoligo), producing high affinity and selective DNA aptamers “Xenoligo®”, whereas Chiome is pursuing development of unique therapeutic monoclonal antibody(ies).
Conjugating Xenoligo with Chiome’s monoclonal antibodies will generate bispecific molecules that have the potential to further enhance the functionality of potential therapeutic agents.
Dr Chizuko Koseki, Chief Executive Officer of TAGCyx added “we are pleased to enter into a collaboration with Chiome, bringing together 2 leading technologies to potentially enhance therapeutic research”
TAGCyx will organize “Aptamer Seminar in Tokyo” on October 4th 2019.
Aptamer Seminar in Tokyo
4th October 2019 (Friday) 13:00-19:00
TKP Tokyo Station Nihonbashi Conference Centre、Room 218
〒103-0028 Tōkyō-to, Chuo City, Yaesu, 1-chōme−2−16 TG Bldg （No parking）
13:00 Opening Remarks (Dr. Koseki)
13:15 Dr. Jean-Jacques Toulmé
Research Director, Emeritus, Inserm; – Scientific Director, Co-founder at Novaptech
“Aptasensing small molecules”
14:05 Dr. Ichiro Hirao
Founder of TAGCyx Biotechnologies Inc.
Covering Executive Director, Team Leader and Principal Research Scientist
Institute of Bioengineering and Nanotechnology, A*STAR (Singapore)
“High-affinity and high-specificity DNA aptamer generation by genetic alphabet expansion”
14:55 Dr. Shinsuke Sando
Professor, Department of Chemistry & Biotechnology, Department of Bioengineering (adjunct), School of Engineering, The University of Tokyo
“Aptamers for controlling cellular functions and fates”
15:45- 16:00 Break time
16:00 Dr. Keitaro Yoshimoto
Associate Prof., PI, Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo,
“Magnetic-beads Assisted Capillary Electrophoresis (MACE) for Aptamer Selection”
16:50 Dr. Chizuko Koseki
President and CEO TAGCyx Biotechnologies
“Xenoligo® drug discovery and development using unnatural base pair technology”
17:40 Closing remarks
17:50 -19:00 Networking
Registration fee: 1000 JPY/person
TITLE: Inhibitory Effect of a Novel DNA Aptamer with Artificial Nucleic Bases for Von Willebrand Factor A1 Domain on Platelet Thrombosis FormationAmerican Society of Hematology
the American Society of Hematology, the 60th Annual Meeting and Exposition (December 1-4, 2018) in San Diego ,
CA Session Name: 332. Anti-thrombotic Therapy: Poster II
Date: Sunday, December 2, 2018 at 6PM PDT
Authors: Kazuya Sakai1, Hideo Yagi1, Masaki Hayakawa1, Tatsuhiko
Someya2, Kaori Harada2, and Masanori Matsumoto1 1. Department of
Blood Transfusion Medicine, Nara Medical University, Nara, Japan 2.
TAGCyx Biotechnologies Inc, Tokyo, Japan
The conference information will be found here.
Date: October 10th-12th 2018
Place: Pacifico Yokohama 1-1-1 Minato Mirai, Nishi-ku, Yokohama 220-0012, Japan
Conference details are found here.